title: Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study.
abstract: BACKGROUND
  In stage IV rectal cancer, palliative surgery is often carried out upfront. This study investigated whether the surgery can be avoided.
  
  
  METHODS
  Forty patients with symptomatic primary rectal adenocarcinoma and synchronous distant metastases deemed to be unresectable received 5 × 5 Gy irradiation and then oxaliplatin-based chemotherapy. Before treatment, 38% of patients had a near-obstructing lesion. The palliative effect was evaluated by questionnaires completed by the patients.
  
  
  RESULTS
  The median follow-up for living patients was 26 months (range 19-34). The median overall survival was 11.5 months. Eight patients (20%) required surgery during the course of their disease: seven patients required stoma creation and one had local excision. Thirty percent of patients had a complete resolution of pelvic symptoms during the whole course of the disease, and 35% had significant improvement. In the subgroup with a near-obstructing lesion, 23% of patients required stoma creation. In all patients, the probability of requiring palliative surgery at 2 years was 17.5% [95% confidence interval (CI) 13% to 22%), and the probability of sustained good palliative effect after radiotherapy and chemotherapy was 67% (95% CI 58% to 76%).
  
  
  CONCLUSIONS
  Short-course radiotherapy and chemotherapy allowed most patients to avoid surgery, even those with a near-obstructing lesion.
  
  
  RESULTS
  The trial is registered with ClinicalTrials.gov: number NCT01157806.
authors.affiliation: Department of Radiotherapy.
authors.forename: D
authors.initials: D
authors.lastname: Tyc-Szczepaniak
authors.forename: L
authors.initials: L
authors.lastname: Wyrwicz
authors.forename: L
authors.initials: L
authors.lastname: Kepka
authors.forename: W
authors.initials: W
authors.lastname: Michalski
authors.forename: M
authors.initials: M
authors.lastname: Olszyna-Serementa
authors.forename: J
authors.initials: J
authors.lastname: Palucki
authors.forename: L
authors.initials: L
authors.lastname: Pietrzak
authors.forename: A
authors.initials: A
authors.lastname: Rutkowski
authors.forename: K
authors.initials: K
authors.lastname: Bujko
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000628:therapy; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010166:Palliative Care; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil
keywords: palliative radiotherapy; stage IV rectal cancer